<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4481">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03048591</url>
  </required_header>
  <id_info>
    <org_study_id>E2016014A</org_study_id>
    <nct_id>NCT03048591</nct_id>
  </id_info>
  <brief_title>The Exploratory Study of Electroacupuncture in the Treatment of Peripheral Neuropathy Induced by Platinum Based Chemotherapy Drugs</brief_title>
  <official_title>The Exploratory Study of Electroacupuncture in the Treatment of Peripheral Neuropathy Induced by Platinum Based Chemotherapy Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Through the research to confirm the effectiveness and safety of using electroacupuncture in
      the treatment of chemotherapy-induced peripheral neuropathy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 21, 2017</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy (QLQ-CIPN20)</measure>
    <time_frame>three months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Treatment - General scale（FACT-G）</measure>
    <time_frame>three months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Chemotherapy-induced Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Electroacupuncture group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>electroacupuncture</intervention_name>
    <description>Acupoint selection: Bilateral Hegu (LI4), Qu-chi (LI1) of upper limbs and bilateral Zusanli (ST36) ,Taichung (LR3)of lower limbs.</description>
    <arm_group_label>Electroacupuncture group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The histopathological and / or cellular pathology results prove malignancy of the
             tumor and the patient has received chemotherapy treatment before.

          2. 15weeks after the completion of chemotherapy, the limbs are still feeling abnormal
             and the symptoms fulfill World Health Organization (WHO) grade 2 or more.

          3. zubrod - Eastern Cooperative Oncology Group-WHO (ZPS) grade 0-2, cardiac function,
             liver function and renal function are not significantly abnormal, the survival period
             of the patient is expected to be more than 6 months.

          4. Gender unrestricted, aged between 18 to 80 years old.

          5. Voluntary participation in the study, will to sign informed consent, willing to
             comply with randomized grouping, will to follow-up.

        Exclusion Criteria:

          1. Patients who suffer from peripheral neuropathy due to infection, radiotherapy, HIV,
             chronic alcoholism, hypothyroidism, diabetes, paraneoplastic syndrome or other
             diseases; or are suffering from nervous system diseases.

          2. Patients who are being treated with other drugs that may lead to neurotoxicity .

          3. Patients with blood coagulation disorder.

          4. Pregnancy and lactating women.

          5. Patients with infection, scarring or defects near the acupoint sites.

          6. Received intervention for the prevention and treatment of peripheral neuropathy 2
             weeks before screening or has received traditional Chinese medicine (acupuncture,
             moxibustion, cupping, Chinese medicine therapy one month before.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bin Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bin Wang</last_name>
    <email>wbin8888@163.com</email>
  </overall_contact>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 20, 2017</lastchanged_date>
  <firstreceived_date>February 7, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin Medical University Cancer Institute and Hospital</investigator_affiliation>
    <investigator_full_name>Bin Wang</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
